Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;28(1):92-103.
doi: 10.1177/15910199211015042. Epub 2021 May 4.

P2Y12 inhibitors for the neurointerventionalist

Robin J Borchert  1 , Davide Simonato  2   3 , Charlotte R Hickman  4 , Maurizio Fuschi  2 , Lucie Thibault  5 , Hans Henkes  6 , David Fiorella  6 , Benjamin Yq Tan  6 , Leonard Ll Yeo  6 , Hegoda L D Makalanda  7 , Ken Wong  7 , Pervinder Bhogal  6
Affiliations
Review

P2Y12 inhibitors for the neurointerventionalist

Robin J Borchert et al. Interv Neuroradiol. 2022 Feb.

Abstract

The use of antiplatelets is widespread in clinical practice. However, for neurointerventional procedures, protocols for antiplatelet use are scarce and practice varies between individuals and institutions. This is further complicated by the quantity of antiplatelet agents which differ in route of administration, dosage, onset of action, efficacy and ischemic and hemorrhagic complications. Clarifying the individual characteristics for each antiplatelet agent, and their associated risks, will increasingly become relevant as the practice of mechanical thrombectomy, stenting, coiling and flow diversion procedures grows. The aim of this review is to summarize the existing literature for the use of P2Y12 inhibitors in neurointerventional procedures, examine the quality of the evidence, and highlight areas in need of further research.

Keywords: Antiplatelets; aneurysm; hemorrhage; stroke; thrombectomy.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Platelet activation pathways targeted by established and emerging antiplatelet drugs.
See this image and copyright information in PMC

References

    1. Simonato D, Borchert R, Labeyrie M-A, et al. Glycoprotein IIb/IIIa inhibitors for the neurointerventionalist. Interv Neuroradiol. In press. - PMC - PubMed
    1. Karaźniewicz-Łada M, Danielak D, Burchardt P, et al. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet 2014; 53: 155–164. - PMC - PubMed
    1. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50: 126–142. - PubMed
    1. Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 2017; 136: 1955–1975. - PubMed
    1. Frelinger AL, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and Pre-Existent variability in platelet function. J Am Coll Cardiol 2013; 61: 872–879. - PubMed

MeSH terms

Substances

LinkOut - more resources